more

McKesson (MCK)

(Delayed Data from NYSE)

$597.45 USD

+7.50 (1.27%)

Updated Jun 17, 2024 04:00 PM ET

After-Market: $597.73 +0.28 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

Bottom 29% (178 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Top Ranked Value Stocks to Buy for October 18th

by Zacks Equity Research Published on October 18,2019

Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 18th.

medical

Here's Why You Should Add PRA Health to Your Portfolio Now

by Zacks Equity Research Published on October 17,2019

PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry.

medical

Here's Why You Should Add Allscripts to Your Portfolio Now

by Zacks Equity Research Published on October 16,2019

Allscripts' (MDRX) focus on innovation makes it a worthy investment pick.

medical

Here's Why You Should Retain Intuitive Surgical for Now

by Zacks Equity Research Published on October 16,2019

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction continues to raise concern.

medical

Here's Why You Should Hold on to NextGen Healthcare for Now

by Zacks Equity Research Published on October 15,2019

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

medical

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research Published on October 15,2019

CONMED (CNMD) raises 2019 revenue and earnings per share guidance.

medical

Top Ranked Value Stocks to Buy for October 15th

by Zacks Equity Research Published on October 15,2019

Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 15th.

Here's Why You Should Retain Ecolab (ECL) Stock For Now

by Zacks Equity Research Published on October 14,2019

Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

medical

Dental Supplies Industry's Near-Term Outlook Looks Bright

by Sreyoshi Mukherjee Published on October 14,2019

With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.

medical

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research Published on October 10,2019

PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

medical

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research Published on October 10,2019

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.

medical

Is McKesson (MCK) Stock Undervalued Right Now?

by Zacks Equity Research Published on October 10,2019

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MCKPositive Net Change

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research Published on October 09,2019

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.

medical

Integer Holdings (ITGR) Boosts Product Line with New Buyout

by Zacks Equity Research Published on October 09,2019

Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.

medical

Top Ranked Value Stocks to Buy for October 8th

by Zacks Equity Research Published on October 08,2019

Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 8th

Can McKesson (MCK) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research Published on October 04,2019

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.